作者
Ya'an Kang, Rafal Zielinski, Roberto Cardenas Zuniga, Radjendirane Venugopal, Maria Poimenidou, Magdalena Remiszewski, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Van N Nguyen, Izabela Fokt, Waldemar Priebe
发表日期
2021/11/15
期刊
Cancer Research
卷号
81
期号
22_Supplement
页码范围
PO-066-PO-066
出版商
The American Association for Cancer Research
简介
Introduction: Annamycin (ANN) is a non-cardiotoxic potent topoisomerase II poison that is structurally related to doxorubicin (Dox) but it displays significantly different biological properties. ANN is formulated in multilamellar liposomes to enable effective in vivo administration as L-ANN. Pancreatic ductal adenocarcinoma (PDAC) represents a major challenge and is the deadliest cancer in decades. Pancreas drug uptake and retention remains a significant factor contributing to the chemoresistance of PDAC. Additionally, drug resistance on a cellular level further limits the therapeutic options for pancreatic cancer patients. Based on unique biological properties, we select L-ANN for detailed characterization of anti-tumor potency in preclinical PDAC models. Objective: The objective of this study was to validate the L-ANN exceptional uptake in pancreatic cancer cells and tumors and explore its high pancreas uptake to …
学术搜索中的文章